Technical Analysis for IMNP - Immune Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 0.0032 -39.62% -0.0021
IMNP closed down 39.62 percent on Tuesday, February 19, 2019, on 3.35 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical IMNP trend table...

Date Alert Name Type % Chg
Volume Surge Other 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Spinning Top Other -39.62%
Narrow Range Bar Range Contraction -39.62%

Older signals for IMNP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On February 17, 2019, Immune Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.
Medicine Medical Specialties Biopharmaceutical Life Sciences Pain U.S. Bankruptcy Court Immunology Autoimmune Diseases Psoriasis Antibody Atopic Dermatitis Stage Biopharmaceutical Ulcerative Colitis Acute Myeloid Leukemia Pain Products Bertilimumab Diabetic Peripheral Neuropathy U.S. Bankruptcy Court For The District Of New Jersey
Is IMNP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 0.17
52 Week Low 0.0023
Average Volume 8,693,572
200-Day Moving Average 0.0
50-Day Moving Average 0.0091
20-Day Moving Average 0.0069
10-Day Moving Average 0.0066
Average True Range 0.0026
ADX 21.28
+DI 22.0056
-DI 24.5125
Chandelier Exit (Long, 3 ATRs ) 0.0081
Chandelier Exit (Short, 3 ATRs ) 0.0101
Upper Bollinger Band 0.0093
Lower Bollinger Band 0.0045
Percent B (%b) -0.27
BandWidth 69.565217
MACD Line -0.0013
MACD Signal Line -0.0014
MACD Histogram 0.0001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0074
Resistance 3 (R3) 0.0076 0.0063 0.0067
Resistance 2 (R2) 0.0063 0.0053 0.0063 0.0065
Resistance 1 (R1) 0.0048 0.0046 0.0042 0.0046 0.0062
Pivot Point 0.0035 0.0035 0.0032 0.0035 0.0035
Support 1 (S1) 0.0020 0.0025 0.0014 0.0018 0.0002
Support 2 (S2) 0.0007 0.0018 0.0007 -0.0001
Support 3 (S3) -0.0008 0.0007 -0.0003
Support 4 (S4) -0.0010